Effect of slow release pentoxifylline and captopril on delayed pulmonary complications of mustard gas in animal models

Tanaffos

Volumn 8, Issue 1, 2009, Pages 41-49

  Pardakhti, Abbas ^a   Alavi, Seyed Ali ^b   Kheshti, Nooshin Mir ^b   Eshaghi, Peyman ^b   Safaeian, Leili ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Hakimane Shagh Research Institute   (Iran)

Author keywords

Captopril; Lung; Pentoxifylline; Slow release pump; Sulfur mustard

Indexed keywords

CAPTOPRIL; MUSTARD GAS; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG RELEASE; FEMALE; IMAGE ANALYSIS; LUNG DISEASE; LYMPHOCYTE; MOUSE; NONHUMAN;

EID: 77249177184     PISSN: 17350344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 2005; 19 (3): 297-315.
2. Papirmeister B; Feister AJ; Rabinson SI; et al. Medical defense against mustard gas: toxic mechanism and pharmacological implications. Florida: CRC Press; 1991; p180-99.
3. Meier HL,Millard CB. Alterations in human lymphocyte DNA caused by sulfur mustard can be mitigated by selective inhibitors of poly(ADP-ribose) polymerase. Biochim Biophys Acta 1998; 1404(3) :367-76.
4. Moser J, Meier HL. Comparison of cell size in sulfur mustard-induced death of keratinocytes and lymphocytes. J Appl Toxicol 2000; 20 Suppl 1: S23-30.
5. Papirmeister B; Feister AJ; Ford RD. Medical Defense against mustard gas: Toxic mechanisms and pharmacological implications. Florida: CRC Press; 1991; p 6-23.
6. Willems JL. Clinical management of mustard gas casualties. Ann Med Milit 1989; 3: 1-61.
7. Balali M. Clinical and laboratory findings in Iranian fighters with chemical gas poisoning. Arch Belg 1984; Suppl: 254-9.
8. rd European International Meeting. Ghent, 24-27 August.
9. Han S, Espinoza LA, Liao H, Boulares AH, Smulson ME. Protection by antioxidants against toxicity and apoptosis induced by the sulphur mustard analog 2-chloroethylethyl sulphide (CEES) in Jurkat T cells and normal human lymphocytes. Br J Pharmacol 2004; 141 (5): 795-802. Erratum in: Br J Pharmacol 2004; 142 (1): 229.
10. th ed. Philadelphia: WB Saunders company 2003; p9-11.
11. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest 1999; 115 (5): 1346-51.
12. Aghanouri R, Ghanei M, Aslani J, Keivani-Amine H, Rastegar F, Karkhane A. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287 (6): L1160-4.
13. Lazarczyk M, Grzela T, Niderla J, Golab J, Korczak-Kowalska G, Oldak M, et al. Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. Oncol Rep 2003; 10 (4): 839-43.
14. Currie MS, Rao KM, Padmanabhan J, Jones A, Crawford J, Cohen HJ. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990; 47 (3): 244-50.
15. Sourbier P; Perianin A; Hakim J. In vitro effect of pentoxifylline on human neutrophil function. In: Mandell GL; Novick WJ. Pentoxifylline and leucocyte function. Hoechst-Roussel Pharm Inc., FL, USA 1987; p56-67
16. Takehana H, Inomata T, Niwano H, Nishii M, Matsuda C, Kohno K, et al. Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis. Circ J 2002; 66 (5): 499-504.
17. Marcinkiewicz J, Grabowska A, Lauterbach R, Bobek M. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology 2000; 49 (3): 335-43.
18. Shukla V, Gude RP. Amelioration of B16F10 melanoma cells induced oxidative stress in DBA/2 mice by pentoxifylline. J Exp Clin Cancer Res 2003; 22 (3): 407-10.
19. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005; 59 (6): 302-6.
20. Helfman T, Falanga V. Gene expression in low oxygen tension. Am J Med Sci 1993; 306 (1): 37-41.
21. Falanga V, Martin TA, Takagi H, Kirsner RS, Helfman T, Pardes J, et al. Low oxygen tension increases mRNA levels of alpha 1 (I) procollagen in human dermal fibroblasts. J Cell Physiol 1993; 157 (2): 408-12.
22. Vujaskovic Z, Anscher MS, Feng QF, Rabbani ZN, Amin K, Samulski TS, et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 2001; 50 (4): 851-5.
23. rd ed. Philadelphia: WB Saunders Company 2000; p1675-6.
24. th ed. London: pharmaceutical press 2005; p980.
25. Candan F, Alagözlü H. Captopril inhibits the pulmonary toxicity of paraquat in rats. Hum Exp Toxicol 2001; 20 (12): 637-41.
26. Uhal BD, Wang R, Laukka J, Zhuang J, Soledad-Conrad V, Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol Toxicol 2003; 92 (2): 81-7.
27. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radial Biol 2000; 76 (4): 523-32.
28. th ed. London: pharmaceutical press 2005; p879.
29. WOESSNER JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Blechem Biophys 1961; 93: 440-7.
30. Kremer S, Breuer R, Lossos IS, Berkman N, Christensen TG, Connor MW, Goldstein RH, Or R. Effect of immunomodulators on bleomycin-induced lung injury. Respiration 1999; 66 (5): 455-62.
31. Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45 (11): 1136-43.
32. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas induced pulmonary fibrosis. Chest 1999; 115: 1346-51.
33. Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997; 112 (3): 734-8.
34. Papirmeister B; Feister AJ; Ford RD. Medical defense against mustard gas: toxic mechanisms and pharmacological implications. Florida: CRC Press 1991; p66-70.
35. Arroyo CM, Burman DL, Kahler DW, Nelson MR, Corun CM, Guzman JJ, et al. TNF-alpha expression patterns as potential molecular biomarker for human skin cells exposed to vesicant chemical warfare agents: sulfur mustard (HD) and Lewisite (L). Cell Biol Toxicol 2004; 20 (6): 345-59.
36. Entzian P, Zähringer U, Schlaak M, Gerlach C, Galle J, Zabel P. Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis. Int J Immunopharmacol 1998; 20 (12): 723-35.
37. Entzian P, Gerlach C, Gerdes J, Schlaak M, Zabel P. Pentoxifylline inhibits experimental bleomycin-induced fibrosing alveolitis, Pneumologie 1997; 51 (4): 375-80.
38. Kremer S, Breuer R, Lossos IS, Berkman N, Christensen TG, Connor MW, et al. Effect of immunomodulators on bleomycin-induced lung injury. Respiration 1999; 66 (5): 455-62.